MRNAModerna, Inc.

Nasdaq modernatx.com


$ 116.09 $ -1.12 (-0.96 %)    

Wednesday, 03-Jul-2024 12:59:59 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 115.95
$ 118.15
$ 0.00 x 0
$ 0.00 x 0
$ 115.36 - $ 119.25
$ 62.55 - $ 170.47
1,851,589
na
44.29B
$ 0.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 10-30-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-27-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-moderna-stock-wednesday

Moderna announced a $176 million award for the development of an mRNA-based Influenza vaccine.

 mrna-technology-promises-to-make-a-long-time-coming-turning-point-in-cancer-treatment

The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame duri...

 london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents

Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 amid-rapidly-rising-bird-flu-cases-moderna-lands-176m-worth-us-government-contract-for-vaccine

The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1...

 moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23---june-29-are-these-in-your-portfolio

10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com,...

 whats-going-on-with-moderna-stock-friday

Moderna's RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RS...

 needham-reiterates-hold-on-moderna

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.

Core News & Articles

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...

 piper-sandler-reiterates-overweight-on-moderna-maintains-214-price-target

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and maintains $214 price target.

 evercore-isi-group-maintains-in-line-on-moderna-maintains-120-price-target

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:MRNA) with a In-Line and maintains $120 price target.

 cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-negative-for-gsk

The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is app...

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 why-is-moderna-stock-trading-lower-on-wednesday

The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 v...